Washington,
D.C. 20549
FORM
6-K
REPORT
OF
FOREIGN ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For
the month of August 2007
Commission
File Number 000-51122
pSivida
Limited
(Translation
of registrant’s name into English)
Level
12 BGC Centre
28
The Esplanade
Perth
WA 6000
Australia
(Address
of principal executive offices)
(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F).
Form
20-F
ý Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
ý
If
"Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ___.
The
document attached as Exhibit 99.1 to this Report on Form 6-K is hereby
incorporated by reference herein and into the following registration statements:
(i) the Registrant's Registration Statement on Form F-3, Registration
No. 333-132776; (ii) the Registrant's Registration Statement on
Form F-3, Registration No. 333-132777; (iii) the Registrant's
Registration Statement on Form F-3, Registration No. 333-135428; (iv)
the Registrant's Registration Statement on Form F-3, Registration
No. 333-141083; (v) the Registrant's Registration Statement on
Form F-3, Registration No. 333-141091; and (vi) the Registrant's
Registration Statement on Form F-3, Registration
No. 333-143225.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
Date:
August
3, 2007
| PSIVIDA LIMITED | ||
| |
|
|
| By: | /s/ Michael J. Soja | |
|
Michael J. Soja |
||
| Vice President, Finance and Chief Financial Officer | ||
EXHIBIT
INDEX
|
EXHIBIT
99.1:
|
Press
Release: pSivida Strengthens Board with the Appointment of an Australian
based Non-executive
Director
|
pSivida
Strengthens Board with the Appointment
of
an Australian based Non-executive Director
Boston,
MA and Perth, Australia (August 3, 2007) - pSivida Limited (NASDAQ:PSDV,
ASX:PSD, Xetra:PSI) today announced the appointment of Dr. Katherine Woodthorpe
based in Sydney, Australia as a Non-executive Director of the Company.
Dr.
Woodthorpe is currently the Chief Executive of AVCAL, the Australian Private
Equity and Venture Capital Association. Dr. Woodthorpe has an extensive
background as a management adviser and director, including working with
Australian technology companies seeking venture funding to being a board
member
of listed companies. She has consulted with government groups on innovation
and
commercialization.
With
more
than 25 years in the technology and commercialization industry, Dr. Woodthorpe
has held a broad range of management and board positions. In addition to
her
role as Chief Executive of the AVCAL, Dr. Woodthorpe is Chair of the Antarctic
Climate and Ecosystems Cooperative Research Centre, Director of Insearch
Ltd and
Council Member, University of Technology Sydney.
“We
are
very fortunate to have Katherine join the Board,” said pSivida’s Managing
Director, Dr. Paul Ashton. “Katherine brings a unique and powerful blend of
scientific and business skills that we believe will greatly assist pSivida.”
Prior
to
AVCAL, Dr. Woodthorpe worked as a professional Non-Executive Director and
management adviser. Her areas of expertise included developing strategies
for
rapid growth and commercialization of technology products and services.
Mr.
Stephen Lake who joined the Board in July 2004 has decided to stand down
as a
Director to can focus on the launch of a new technology fund in the UK.
pSivida
Non-executive Chairman, Dr. David Mazzo said, “Mr. Lake has provided invaluable
assistance in bringing pSivida through and into a new phase of development
and
the Company thanks Mr. Lake for his significant contribution over the last
three
years and wishes Mr. Lake well in his new ventures”.
Released
by:
|
pSivida
Limited
Brian
Leedman
Vice
President, Investor Relations
pSivida
Limited
Tel:
+ 61 8 9226 5099
bleedman@psivida.com
|
US
Public Relations
Beverly
Jedynak
President
Martin
E. Janis & Company, Inc
Tel:
(312) 943 1103
bjedynak@janispr.com
|
European
Public Relations
Eva
Reuter
Accent
Marketing Limited
Tel:
+49 (254) 393 0740
e.reuter@dr-reuter.eu
|
NOTES
TO EDITORS:
pSivida
is a global drug delivery company committed to the biomedical sector. .Retisert®
is FDA approved for the treatment of uveitis. Vitrasert® is FDA approved for the
treatment of AIDS-related CMV Retinitis. Bausch & Lomb owns the trademarks
Vitrasert® and Retisert®. pSivida has licensed the technologies underlying both
of these products to Bausch & Lomb. The technology underlying Medidur™ for
diabetic macular edema is licensed to Alimera Sciences and is in Phase III
clinical trials. pSivida has a worldwide collaborative research and license
agreement with Pfizer Inc. for other ophthalmic applications of the Medidur™
technology.
pSivida
owns the rights to develop and commercialize a modified form of silicon
(porosified or nano-structured silicon) known as BioSilicon™, which has
applications in drug delivery, wound healing, orthopedics, and tissue
engineering. The most advanced BioSilicon™ product, BrachySil™ delivers a
therapeutic, P32 directly to solid tumors and is presently in Phase II clinical
trials for the treatment of pancreatic cancer.
pSivida’s
intellectual property portfolio consists of 71 patent families, 99 granted
patents, including patents accepted for issuance, and over 300 patent
applications. pSivida conducts its operations from facilities near Boston
in the
United States, Malvern in the United Kingdom and Perth in
Australia.
pSivida
is listed on NASDAQ (PSDV),
the
Australian Stock Exchange (PSD)
and on
the Frankfurt Stock Exchange on the XETRA system (PSI).
pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
Lynch Nanotechnology Index.
This
release contains forward-looking statements that involve risks and
uncertainties. Although we believe that the expectations reflected in such
forward-looking statements are reasonable at this time, we can give no assurance
that such expectations will prove to be correct. Given these uncertainties,
readers are cautioned not to place undue reliance on such forward-looking
statements. Actual results could differ materially from those anticipated
in
these forward-looking statements due to many important factors that are
contained in cautionary statements in the Annual Report on Form 20-F filed
with
the U.S. Securities and Exchange Commission, including, without limitation,
under Item 3.D, "Risk Factors" therein. We do not undertake to update any
oral
or written forward-looking statements that may be made by or on behalf of
pSivida.
-2-